Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech Will Develop Long-Acting Growth Hormone Under Licensing Deal With Altus

This article was originally published in The Pink Sheet Daily

Executive Summary

The growth hormone candidate offers once-weekly dosing for adults and children.

You may also be interested in...



Genentech Returns Long-Acting Growth Hormone Candidate To Altus

Genentech/Roche anti-cancer drug Avastin wins European approval for first-line use in advanced kidney cancer.

Genentech Returns Long-Acting Growth Hormone Candidate To Altus

Genentech/Roche anti-cancer drug Avastin wins European approval for first-line use in advanced kidney cancer.

Altus Pushes Back Phase III Timeline On Lead Products

Inconsistencies in a test lot of Altus’ oral pancreatic enzyme insufficiency product deferred one trial; failure of a supplier to deliver critical equipment postponed a trial for its human growth hormone product.

Related Content

Topics

UsernamePublicRestriction

Register

RS150923

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel